Can Fite Biofarma Ltd (CANF)

2.11
0.02 1.15
AMEX : Health Care
Prev Close 2.13
Open 2.18
Day Low/High 2.11 / 2.18
52 Wk Low/High 1.46 / 7.85
Volume 16.79K
Avg Volume 99.20K
Exchange AMEX
Shares Outstanding 13.84M
Market Cap 29.47M
EPS -0.40
P/E Ratio 3.49
Div & Yield N.A. (N.A)

Latest News

Can-Fite Reports New Data Showing Its Psoriasis Drug May Offer Efficacy Similar To Industry Leading Biologics Without Harmful Side Effects

Can-Fite Reports New Data Showing Its Psoriasis Drug May Offer Efficacy Similar To Industry Leading Biologics Without Harmful Side Effects

- Similar to biologics, Piclidenoson (CF101) inhibits inflammatory proteins IL-17 and IL-23

Can-Fite Submits Psoriasis Phase III Protocol And Registration Plan To EMA For Piclidenoson (CF101)

Can-Fite Submits Psoriasis Phase III Protocol And Registration Plan To EMA For Piclidenoson (CF101)

- Phase III protocol is a head-to-head trial comparing Piclidenoson to Otezla®

Can-Fite To Exhibit At Bio International Convention In San Francisco On June 6-9, 2016

Can-Fite To Exhibit At Bio International Convention In San Francisco On June 6-9, 2016

Company also to participate as a member of the Israeli Biotech Delegation at Perspectives on Biotech Investing on June 6

Can-Fite Reaches Agreement With EMA On Pivotal Phase III Clinical Trial With Piclidenoson (CF101) In Rheumatoid Arthritis

Can-Fite Reaches Agreement With EMA On Pivotal Phase III Clinical Trial With Piclidenoson (CF101) In Rheumatoid Arthritis

- EMA suggests development of Piclidenoson as a first line therapy and alternative for methotrexate, the standard of care for rheumatoid arthritis

Can-Fite BioPharma (CANF) Stock Jumps on Positive Pre-Clinical Data

Can-Fite BioPharma (CANF) Stock Jumps on Positive Pre-Clinical Data

Can-Fite BioPharma (CANF) stock is gaining on Monday afternoon as the company announced pre-clinical data for CF602, which demonstrated statistically significant full recovery from erectile dysfunction after a single dose.

Can-Fite Announces New Pre-Clinical Data For CF602 Demonstrating Statistically Significant Full Recovery From Erectile Dysfunction After A Single Dose

Can-Fite Announces New Pre-Clinical Data For CF602 Demonstrating Statistically Significant Full Recovery From Erectile Dysfunction After A Single Dose

CF602 may provide benefits for patients who cannot take or do not respond to erectile dysfunction drugs currently on the market

Can-Fite CEO Dr. Pnina Fishman To Chair Scientific Session At The 2016 Purinergic Signaling And Cancer Immunotherapy Conference In Vancouver On January 26, 2016

Can-Fite CEO Dr. Pnina Fishman To Chair Scientific Session At The 2016 Purinergic Signaling And Cancer Immunotherapy Conference In Vancouver On January 26, 2016

Dr. Fishman is one of a select number of global Key Opinion Leaders on drugs targeting A3AR receptors

U.S. Patent & Trademark Office Issues Notice Of Allowance For Can-Fite's Sexual Dysfunction Drug CF602

U.S. Patent & Trademark Office Issues Notice Of Allowance For Can-Fite's Sexual Dysfunction Drug CF602

- Composition of matter patent protects use of an A3AR modulator for the treatment of any indication

Can-Fite Announces 2016 Clinical Milestones For Its Pipeline Of Drugs In Six Indications

Can-Fite Announces 2016 Clinical Milestones For Its Pipeline Of Drugs In Six Indications

- Phase III trials in rheumatoid arthritis and psoriasis expected to commence in 2016

Can-Fite Submits Phase III Protocol To IRB For CF101 In The Treatment Of Rheumatoid Arthritis

Can-Fite Submits Phase III Protocol To IRB For CF101 In The Treatment Of Rheumatoid Arthritis

- Pivotal Phase III trial to enroll approximately 456 patients for robust statistically significant data

Can-Fite's CF101 Granted Patent In Japan For Intraocular Pressure A Key Cause Of Glaucoma

Can-Fite's CF101 Granted Patent In Japan For Intraocular Pressure A Key Cause Of Glaucoma

- CF101's Phase II glaucoma trial recently completed enrollment- Glaucoma market is estimated to reach $3 billion by 2023

OphthaliX Announces CF101 Is Granted Patent In Japan For Intraocular Pressure A Key Cause Of Glaucoma

OphthaliX Announces CF101 Is Granted Patent In Japan For Intraocular Pressure A Key Cause Of Glaucoma

- CF101's Phase II glaucoma trial recently completed enrollment

Can-Fite Subsidiary, OphthaliX, Announces Completion Of Patient Enrollment In Phase II Glaucoma Study For CF101

Can-Fite Subsidiary, OphthaliX, Announces Completion Of Patient Enrollment In Phase II Glaucoma Study For CF101

CF101 is one of only a few oral drugs being developed for the glaucoma market estimated to be $3 billion in 2023

OphthaliX Announces Completion Of Patient Enrollment In Phase II Glaucoma Study For CF101

OphthaliX Announces Completion Of Patient Enrollment In Phase II Glaucoma Study For CF101

CF101 is one of only a few oral drugs being developed for the glaucoma market estimated to be $3 billion in 2023

Can-Fite Announces Compelling Pre-Clinical Data On CF102 In The Treatment Of Non-Alcoholic Steatohepatitis (NASH)

Can-Fite Announces Compelling Pre-Clinical Data On CF102 In The Treatment Of Non-Alcoholic Steatohepatitis (NASH)

- Files patent for CF102 in the treatment of NASH

New Study Demonstrates CF602 Mechanism Of Action To Improve Sexual Dysfunction

New Study Demonstrates CF602 Mechanism Of Action To Improve Sexual Dysfunction

IND submission to FDA is planned for Q3 2016

Can-Fite BioPharma (CANF) Stock Tanks After Pricing Secondary Offering

Can-Fite BioPharma (CANF) Stock Tanks After Pricing Secondary Offering

Can-Fite BioPharma (CANF) shares are down over 10% after pricing its secondary registered direct offering of 1.1 million shares.

Can-Fite BioPharma Announces $4.8 Million Registered Direct Offering

Can-Fite BioPharma Announces $4.8 Million Registered Direct Offering

- Continued Investment from Existing Institutional Investors

European Medicines Agency Grants Orphan Designation To Can-Fite's CF102 In The Treatment Of Liver Cancer

European Medicines Agency Grants Orphan Designation To Can-Fite's CF102 In The Treatment Of Liver Cancer

10-year market exclusivity in Europe following marketing authorization in 31 European Economic Area (EEA) countries